94E.F Zura Bio Limited

Healthcare Biotechnology Frankfurt Exchange
1.26 EUR
Close of Nov 12, 2026
1.06 6.00
Market cap
EUR 121M
P/E
-
P/B
0.64x
ROE
-57.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 94E.F undervalued?

Graham number

The Graham number of Zura Bio Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Zura Bio Limited fundamental analysis

No fundamental analysis for Zura Bio Limited yet.

Zura Bio Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Zura Bio Limited

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targ…

Full company profile